GlassScriptPhysician profile
Rose L Hiner
NPI 1235399817
$12,547.33
in general payments reported to CMS, 2019-2025
51 companies · $2,464 in 2025
The $2,464 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $368 · 2020: $591 · 2021: $1,396 · 2022: $2,157 · 2023: $2,931 · 2024: $2,640 · 2025: $2,464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,985 · Entertainment: $49.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,985.17 |
| Entertainment | $49.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,673.07 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,102.77 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $969.67 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $961.39 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $729.68 | 2019-2025 | |
| Amgen INC. | $392.96 | 2021-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $361.97 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $214.12 | 2022-2025 | Rexulti |
| Sumitomo Pharma America, INC. | $195.66 | 2023-2025 | Gemtesa |
| Axsome Therapeutics, INC. | $194.58 | 2023-2025 | Auvelity, Symbravo |
| Abbott Laboratories | $190.53 | 2022-2025 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $183.44 | 2024-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $168.68 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $166.49 | 2020-2023 | Belsomra, Steglatro |
| Novartis Pharmaceuticals Corporation | $155.13 | 2019-2024 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rose Hiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.